NMT1 and melanoma: The Tris–DBA palladium complex has been proposed to be an NMT1 inhibitor and inhibits growth of melanoma in vitro and in vivo. Furthermore, the same complex also shows promising anticancer activity against multiple myeloma (de la Puente et al., 2016), leukemia B cells (Kay et al., 2016), and prostate cancer (Díaz et al., 2016).